Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, controlled phase 2 trial to compare the
efficacy and safety profiles in ITP patients receiving baricitinib plus danazol to those
receiving danazol alone.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Friendship Hospital Beijing Hospital Beijing Luhe Hospital Beijing Tsinghua Changgeng Hospital China-Japan Friendship Hospital Chinese PLA General Hospital Navy General Hospital, Beijing Peking University First Hospital Peking University Third Hospital